What monitoring is required for patients on Ozempic (semaglutide)?

Monitoring Requirements for Patients on Ozempic (Semaglutide)

Patients on Ozempic require regular A1C monitoring every 3-6 months, blood glucose self-monitoring as appropriate for their regimen, and monitoring for potential adverse effects including gastrointestinal symptoms, diabetic retinopathy, and gallbladder disease.

Core Monitoring Requirements

Glycemic Monitoring

• A1C testing:

  • Perform A1C test at least twice yearly in patients meeting treatment goals with stable glycemic control 1, 2
  • Perform quarterly A1C testing in patients whose therapy has changed or who are not meeting glycemic goals 1, 2
  • Point-of-care A1C testing can provide opportunity for more timely treatment changes 2

• Self-monitoring of blood glucose (SMBG):

  • For patients on non-insulin therapies like Ozempic:
    • SMBG may be helpful when altering diet, physical activity, and/or medications, particularly when there's risk of hypoglycemia 3
    • Not as intensive as for insulin users, but still valuable for guiding treatment decisions 1, 3
  • If combined with insulin therapy:
    • More frequent monitoring required, especially prior to meals, at bedtime, and before critical tasks like driving 1

Adverse Effect Monitoring

• Gastrointestinal effects:

  • Monitor for nausea, vomiting, diarrhea, and abdominal pain, especially during initiation and dose escalation 4, 5
  • These are typically transient and mild-to-moderate in severity 5

• Pancreatitis:

  • Observe for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting) 4
  • No specific laboratory monitoring required, but clinical vigilance is essential

• Diabetic retinopathy:

  • Patients with history of diabetic retinopathy should be monitored for progression 4
  • Rapid improvement in glucose control with Ozempic can be associated with temporary worsening of diabetic retinopathy 4

• Renal function:

  • Monitor for acute kidney injury, especially in patients with underlying renal disease 4
  • Include serum creatinine and calculated GFR in regular laboratory assessments 2

• Hypoglycemia:

  • Increased risk when used with insulin secretagogues or insulin 4
  • More vigilant SMBG may be needed in these combinations

• Gallbladder disease:

  • Be alert for symptoms of cholelithiasis (right upper quadrant pain, nausea) 5

Monitoring Schedule

Initial Period (First 3-6 Months)

1. Baseline A1C before starting therapy
2. Follow-up A1C at 3 months after reaching maintenance dose
3. Clinical assessment for gastrointestinal side effects at each visit
4. Blood glucose monitoring as appropriate for the individual patient

Maintenance Period

1. A1C every 3-6 months (quarterly if not at goal, twice yearly if stable) 2
2. Annual comprehensive metabolic panel to assess liver and kidney function 6
3. Regular eye examinations for patients with pre-existing diabetic retinopathy 4

Special Considerations

• Thyroid monitoring: Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of medullary thyroid carcinoma in patients treated with Ozempic 4

• Continuous glucose monitoring (CGM):

  • May be considered for selected patients, particularly those with hypoglycemia unawareness or frequent hypoglycemic episodes 1, 7
  • Provides more comprehensive picture of glucose levels than intermittent SMBG 8

• COVID-19 considerations:

  • During COVID-19 infection, more intensive glucose monitoring may be needed 9
  • Remote consultations using Connected Health models should be utilized when appropriate 9

Common Pitfalls to Avoid

• Overlooking retinopathy risk: Patients with pre-existing diabetic retinopathy require careful monitoring due to potential worsening with rapid glucose improvement 4

• Ignoring gastrointestinal symptoms: While usually transient, persistent severe abdominal pain could indicate pancreatitis and requires prompt evaluation 4

• Inadequate monitoring in combination therapy: When Ozempic is used with sulfonylureas or insulin, increased monitoring for hypoglycemia is essential 4

• Relying solely on A1C: While A1C is important, it doesn't capture hypoglycemia risk or glycemic variability, which may require additional monitoring strategies 10

By following these monitoring guidelines, clinicians can optimize the safety and efficacy of Ozempic therapy while minimizing the risk of adverse events.